Publikationen

Onkologie

Illini O, Hochmair MJ, Fabikan H, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Therapeutic Advances in Medical Oncology 2021;13:17588359211019675 (writing assistance)

F. Boulmé. RET als therapeutisches Target beim NSCLC und Schilddrüsenkarzinom. SPECTRUM Onkologie e-news. Medahead, Juni 2021. (bit.ly/3w4txf0)

F. Boulmé. RET als onkogener Treiber beim fortgeschrittenen Schilddrüsenkarzinom. SPECTRUM Onkologie e-news. Medahead, Juni 2021. (bit.ly/3x7m5kq)

F. Boulmé. DFP-Literaturstudium. Die Sichelzellerkrankung, Die Punkte:On, MedMedia, Mai 2021.

F. Boulmé. Selpercatinib beim fortgeschrittenen RET-Fusions-positiven nicht-kleinzelligen Lungenkarzinom. Case reports. MedMedia, März 2021. (https://www.medmedia.at/apps/download/download_pdf.php?file=wp-content/uploads/2021/03/2021_Eli_CasR_Selpercatinib.pdf)

F. Boulmé. DFP-Literaturstudium: Die neue Ära der Immuntherapie bei Krebs: die Rolle der praktischen Ärzte. Die Punkte:On, MedMedia Austria, März 2021. (https://www.medmedia.at/diepunkteon/neue-aera-immuntherapie-bei-krebs-rolle-praktische-aerzte/#/)

Hochmair MJ, Prosch H, Krenbek D, Weinlinger C, Fabikan H, Valipour A. Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anticancer Drugs 2021;32(1):105-110 (writing assistance).

F. Boulmé. DFP-Literaturstudium: Real World Evidence. CliniCum Onko, Medizin Medien Austria, September 2020. (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10057611/real-world-evidence/)

F. Boulmé. Positionspapier: Brauchen wir eine Modifikation der mRCC Therapie unter COVID 19? Virtuelles Expertenmeeting, RCC Academy, August 2020. (https://cancercase.net/fileadmin/user_upload/ACADEMY_Events/Positionspapier_RCC_COVID19_Expertenmeeting.pdf)

F. Boulmé. medonline: Onko News (Beiträge). (2020). (https://medonline.at/autoren-und-experten/dr-florence-boulme/)

F. Boulmé. DFP-Literaturstudium: Precision Oncology. CliniCum Onko, Medizin Medien Austria, April 2020. (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10054250/precision-oncology-el/)

F. Boulmé. Lungenkrebs: Todesursache Nummer eins. Ärzte Woche (9), Springer-Verlag, Februar 2020.

Virologie

Pécout C, Pain E, Chekroun M, Champeix C, Kulak C, Prieto R, van Vugt J, Gilchrist K, Lainé-Pellet AF. Impact of the COVID-19 pandemic on patients affected by non-communicable diseases in Europe and in the USA. Int J Environ Res Public Health 2021;18(13):6697 (writing assistance).

M. Traugott, W. Hoepler, R. Kitzberger, S. Pavlata, T. Seitz, S. Baumgartner, G. Placher-Sorko, D. Pirker-Krassnig, U. Ehehalt, A. Grasnek, M. Beham-Kacerovsky, E. Friese, C. Wenisch, S. Neuhold. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2020;15(1):148 (writing assistance).

F. Boulmé. Empfehlungen für die Intensivtherapie von SARS-CoV-2 positiven Patienten. Ärzte Woche (17), Springer-Verlag, April 2020.

F. Boulmé. DFP-Literaturstudium: SARS-CoV-2 im Wartezimmer. Ärzte Woche (12), Springer-Verlag, März 2020. (https://www.springermedizin.at/infektiologie/innere-medizin/sars-cov-2-im-wartezimmer/17805496)

F. Freund, F. Boulmé, S. Litvak, L. Tarrago-Litvak. Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex. Nucleic Acids Res 2001;29, 2757-65.

F. Freund, F. Boulmé, J. Michel, M. Ventura, S. Moreau, S. Litvak. Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex. Antisense Nucleic Acid Drug Dev 2001;11, 301-15.

S. Litvak, M.-L. Andréola, F. Boulmé, F. Freund, R. El-Dirani, E. Dufour, M. Ventura, L. Tarrago-Litvak.(2001) Reverse transcriptase of HIV-1: novel therapeutic interventions” in “Pharmacology of HIV infection and AIDS, edited by Dietmar Fuchs, OICA International Press, Saint-Lucia, London.

F. Boulmé, F. Freund, S. Gryaznov, P. E. Nielsen, L. Tarrago-Litvak, S. Litvak. Study of HIV-2 primer-template initiation complex using antisense oligonucleotides. Eur J Biochem 2000;267, 2803-11.

B. Mestre, A. Arzumanov, M. Singh, F. Boulmé, S. Litvak, M. J. Gait. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999;1445, 86-98.

F. Boulmé. In vitro effect of phosphodiester and chemically modified antisense oligonucleotides on the initiation step of the HIV-1 and HIV-2 reverse transcription. PhD obtained on the 22nd of June1998, University of Bordeaux II, France.

F. Boulmé, F. Freund, S. Moreau, P. E. Nielsen, S. Gryaznov, J.-J. Toulmé, S. Litvak. Modified (PNA, 2’O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res 1998;26, 5492-500.

F. Boulmé, F. Freund, S. Litvak. Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 and HIV-2 RNAs by both type 1 and type 2 reverse transcriptases. FEBS Letters 1998;430, 165-70.

E. Dufour, R. El Dirani-Diab, F. Boulmé, M. Fournier, G. Nevinsky, L. Tarrago-Litvak, S. Litvak, M.-L. Andreola. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: interactions with primer tRNALys3, initiation of cDNA synthesis and effect of inhibitors. Eur J Biochem 1998;251, 487-95.

F. Boulmé, M. Perälä-Heape, L. Sarih-Cottin, S. Litvak. Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochim Biophys Acta 1997;1351, 249-55.

Dermatologie

L. Preibisz, F. Boulmé, ZP. Lorenc. Barbed polydioxanone sutures for face recountouring: six-month safety and effectiveness data supported by objective markerless tracking analysis. Aesthet Surg J 2021; epub ahead a print.

Neurologie

S. Beirer, W. Grisold, J. Dreisbach. Therapy-resistant dysphagia successfully treated using pharyngeal electrical stimulation in a patient with the pharyngeal-cervical-brachial variant of the Guillain-Barré syndrome. eNeurologicalSci 2020;20:100255 (writing assistance).

Hämatologie

*Erste Co-Autorin

F. Boulmé. Diagnostik der Mastozytose. Expertenmeeting, Mai 2021.

F. Boulmé. DFP-Literaturstudium: Die Sichelzellerkrankung. Die Punkte:On, MedMedia Austria, Mai 2021.

F. Boulmé. DFP-Literaturstudium: Diagnostik der systematischen Mastozytose. Die Punkte:On, MedMedia Austria, April 2021. (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10057611/real-world-evidence/)

B. Pradet-Balade, C. Leberbauer, N. Schweifer, F. Boulmé. Massive translational repression of gene expression during mouse erythroid differentiation. Biochim Biophys Acta 2010;1799, 630-41.

C. Leberbauer, *F. Boulmé, G. Unfried, J. Huber, H. Beug, E. Müllner. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 2005;105, 85-94.

M. Joosten, M. Blazquez-Domingo, F. Lindeboom, *F. Boulmé, A. Van Hoven-Beijen, B. Habermann, B. Löwenberg, H. Beug, E. W. Müllner, R. Delwel, M. Von Lindern. Translational control of putative proto-oncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling. J Biol Chem 2004;279, 38169-76.

H. Dolznig, F. Boulmé, K. Stangl, E. M. Deiner, W. Mikulits, H. Beug, E. W. Mülllner. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J 2001;15, 1442-4

Translation Kontrolle

B. Pradet-Balade, F. Boulmé, H. Beug, E. W. Müllner, J. A. Garcia-Sanz. Translation control: bridging the gap between genomics and proteomics?. Trends Biochem Sci 2001;26, 225-9.

B. Pradet-Balade, F. Boulmé, E. W. Müllner, J. A. Garcia-Sanz. Reliability of mRNA profiling: verification for samples with different complexities. Biotechniques 2001;30, 1352-7.